HK1062044A1 - Neurofibrillary labels - Google Patents

Neurofibrillary labels

Info

Publication number
HK1062044A1
HK1062044A1 HK04103802.8A HK04103802A HK1062044A1 HK 1062044 A1 HK1062044 A1 HK 1062044A1 HK 04103802 A HK04103802 A HK 04103802A HK 1062044 A1 HK1062044 A1 HK 1062044A1
Authority
HK
Hong Kong
Prior art keywords
tau
tau protein
derivative
agent
binding
Prior art date
Application number
HK04103802.8A
Other languages
English (en)
Inventor
Claude Michel Wischik
Charles Robert Harrington
Janet Elizabeth Rickard
David Horsley
Original Assignee
Wista Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wista Lab Ltd filed Critical Wista Lab Ltd
Publication of HK1062044A1 publication Critical patent/HK1062044A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/20—[b, e]-condensed with two six-membered rings with hydrogen atoms directly attached to the ring nitrogen atom
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/583—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with non-fluorescent dye label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Hydrogenated Pyridines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Lubricants (AREA)
HK04103802.8A 2001-03-20 2004-05-27 Neurofibrillary labels HK1062044A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0106953.3A GB0106953D0 (en) 2001-03-20 2001-03-20 Neufofibrillary labels
PCT/GB2002/001318 WO2002075318A2 (en) 2001-03-20 2002-03-20 Neurofibrillary labels

Publications (1)

Publication Number Publication Date
HK1062044A1 true HK1062044A1 (en) 2004-10-15

Family

ID=9911161

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04103802.8A HK1062044A1 (en) 2001-03-20 2004-05-27 Neurofibrillary labels

Country Status (13)

Country Link
US (3) US7335652B2 (da)
EP (1) EP1421389B1 (da)
JP (2) JP4288073B2 (da)
CN (2) CN101696977B (da)
AT (1) ATE556323T1 (da)
AU (1) AU2002251172B2 (da)
CA (1) CA2440794C (da)
DK (1) DK1421389T3 (da)
ES (1) ES2386773T3 (da)
GB (1) GB0106953D0 (da)
HK (1) HK1062044A1 (da)
PT (1) PT1421389E (da)
WO (1) WO2002075318A2 (da)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) * 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
GB0113121D0 (en) 2001-05-30 2001-07-18 Univ Leeds Biologically active photosensitisers
GB0117326D0 (en) 2001-07-16 2001-09-05 Univ Aberdeen Napthoquinone-type inhibitors of protein aggregation
CA2529854A1 (en) * 2003-06-19 2004-12-29 Neuronautics, Inc. Methods for inhibiting or reversing tau filament fibrillization
GB0322756D0 (en) * 2003-09-29 2003-10-29 Univ Aberdeen Methods of chemical synthesis
ES2736160T3 (es) 2004-09-23 2019-12-26 Wista Lab Ltd Procedimientos de síntesis química y purificación de compuestos de diaminofenotiazinio que incluyen cloruro de metiltioninio (CMT)
CN101084204B (zh) 2004-09-23 2012-12-05 卫思道制药有限公司 包括亚甲蓝(mtc)在内的二氨基吩噻嗪鎓化合物的化学合成和纯化方法
ES2349322T7 (es) 2006-03-29 2019-10-17 Wista Lab Ltd Sales de 3,7-diamino-10H-fenotiazina y su utilización
WO2007110630A1 (en) 2006-03-29 2007-10-04 Wista Laboratories Ltd. Thioninium compounds and their use
US8263589B2 (en) * 2006-03-29 2012-09-11 Wista Laboratories Ltd. Inhibitors of protein aggregation
JP5132090B2 (ja) * 2006-06-16 2013-01-30 東和薬品株式会社 塩酸エピナスチンドライシロップ剤
PL2057136T3 (pl) 2006-07-11 2013-10-31 Wista Lab Ltd Sposoby syntezy i/lub oczyszczania związków diaminofenotiazynowych
HUE025199T2 (en) 2007-10-03 2016-01-28 Wista Lab Ltd Therapeutic use of diaminophenothiazines
JP2011517666A (ja) * 2008-03-21 2011-06-16 エイディーライフ インコーポレイティッド 血液脳関門を横断してペプチドを運搬するためのピレンの使用
WO2009117042A1 (en) * 2008-03-21 2009-09-24 Adlyfe, Inc. Use of pyrene to carry non-peptide agents across the blood brain barrier
WO2010034982A1 (en) * 2008-09-23 2010-04-01 Wista Laboratories Ltd. Ligands for aggregated tau molecules
PL3112358T3 (pl) 2008-12-10 2020-11-16 Wista Laboratories Ltd. 3,6-Dipodstawione sole ksantyliowe
WO2010067085A2 (en) 2008-12-12 2010-06-17 Wista Laboratories Ltd. Synthesis of 9-(arylalkyl)-1,2,3,4-tetrahydro-υ-carboline and analogues and intermediates
CU23844B1 (es) 2009-04-17 2012-10-15 Ct De Neurociencias De Cuba Procedimiento de obtención de nuevos derivados de naftaleno para el diagnóstico in vivo de la enfermedad de alzheimer
ES2457227T3 (es) 2009-05-12 2014-04-25 Wista Laboratories Ltd. Procedimientos de síntesis química de compuestos de diaminofenotiazinio que implican el uso de oxidantes de persulfato
US8828986B2 (en) 2011-04-20 2014-09-09 Prosetta Antiviral Inc. Antiviral compounds
SG185094A1 (en) 2010-04-30 2012-12-28 Prostetta Antiviral Inc Antiviral compounds
BR112013006016A2 (pt) 2010-09-15 2016-06-07 Hoffmann La Roche compostos de azabenzotiazol, composições e métodos de uso
KR20130129975A (ko) * 2010-11-16 2013-11-29 지이 헬쓰케어 리미티드 타우 병리의 영상화 프로브로서의 헤테로시클릭 화합물
CN103379901B (zh) 2010-11-30 2018-04-03 维斯塔实验室有限公司 含有氯化甲基息奥宁的配方
US20120244174A1 (en) 2011-01-31 2012-09-27 Intellect Neurosciences Inc. Treatment of tauopathies
KR101888713B1 (ko) 2011-02-11 2018-08-14 위스타 레보레이토리스 리미티드 페노티아진 디아미늄 염 및 이의 용도
US9464064B2 (en) 2011-09-07 2016-10-11 University Of Kansas HCV helicase inhibitors and methods of use thereof
CN102942537B (zh) * 2012-11-09 2014-07-02 浙江大学 一种用作pH荧光探针的苯并噻唑-苯胺类化合物及其制备方法
US9296754B2 (en) 2013-03-15 2016-03-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
WO2014151630A2 (en) 2013-03-15 2014-09-25 Irm Llc Compounds and compositions for the treatment of parasitic diseases
US9588129B2 (en) 2013-03-15 2017-03-07 Amira Medical Technologies Inc. Methods for analyzing blood to detect diseases associated with abnormal protein aggregation
US9186361B2 (en) 2013-03-15 2015-11-17 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
US10765755B1 (en) 2013-11-20 2020-09-08 University Of South Florida Preparation and characterization of methylene blue nanoparticles for Alzheimer's disease and other tauopathies
LT3083627T (lt) 2013-12-19 2018-12-27 Novartis Ag [1,2,4]triazolo[1,5-a]pirimidino dariniai kaip protozoano proteasomos inhibitoriai, skirti parazitinių ligų tokių kaip leišmaniozė, gydymui
CN107163022B (zh) * 2016-03-07 2021-07-16 上海如絮生物科技有限公司 一种异喹啉类化合物、其中间体、制备方法和应用
CN110234646A (zh) * 2016-11-01 2019-09-13 阿尔维纳斯股份有限公司 靶向PROTAC的Tau蛋白及相关使用方法
SE540570C2 (en) * 2017-07-14 2018-10-02 A method for analyzing the 3d structure of biomolecules
US11220515B2 (en) 2018-01-26 2022-01-11 Yale University Imide-based modulators of proteolysis and associated methods of use
CN113874078A (zh) 2019-04-05 2021-12-31 Tauc3生物制品有限公司 抗tauc3抗体及其应用
GB201909493D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions
JP7548992B2 (ja) 2019-07-17 2024-09-10 アルビナス・オペレーションズ・インコーポレイテッド タウタンパク質標的化化合物および関連する使用方法
TW202136240A (zh) 2019-12-19 2021-10-01 美商亞文納營運公司 用於靶向降解雄激素受體之化合物及方法
GB202010620D0 (en) 2020-07-10 2020-08-26 Wista Lab Ltd System
GB202010652D0 (en) 2020-07-10 2020-08-26 Wista Lab Ltd Anti-tau antibodies
WO2023135200A1 (en) 2022-01-12 2023-07-20 Gtinvent Limited Method for detecting a tau protein in a saliva sample

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
CA1302250C (en) * 1986-04-04 1992-06-02 Khalid Iqbal Diagnostic for alzheimer's disease
US5008099A (en) * 1987-04-08 1991-04-16 Salutar, Inc. Amyloidosis and Alzheimer's disease diagnostic assay and reagents therefor
EP0287909B1 (en) * 1987-04-08 1992-09-02 Salutar, Inc. Amyloidosis and alzheimer's disease diagnostic assay and reagents therefor
GB8724412D0 (en) 1987-10-19 1987-11-25 Medical Res Council Protein
FI101344B1 (fi) * 1988-03-31 1998-06-15 Tanabe Seiyaku Co Menetelmä valmistaa valmiste, josta kontrolloidusti vapautuu farmaseuttisesti aktiivista ainetta
CA2110488A1 (en) 1991-07-10 1993-01-21 Franceska Fieuws Fluorochemical water- and oil-repellent treating compositions
AU2414092A (en) * 1991-08-01 1993-03-02 Paul H. Voorheis Diagnostic method for alzheimer's disease
ATE438716T1 (de) 1991-12-06 2009-08-15 Max Planck Gesellschaft Verwendung von protein-kinasen zur diagnose und behandlung der alzheimer-krankheit
WO1993019143A1 (en) * 1992-03-17 1993-09-30 Lord Corporation Colorant-containing electrorheological materials
US5536761A (en) * 1992-12-07 1996-07-16 Sakura Color Products Corporation Water base dye ink composition
GB9317193D0 (en) 1993-08-18 1993-10-06 Zeneca Ltd Method
AU708682B2 (en) * 1994-08-08 1999-08-12 Albert Einstein College Of Medicine Of Yeshiva University Methods for treating and/or preventing Alzheimer's disease using phenothiazines and/or thioxanthenes
DE4430091A1 (de) * 1994-08-25 1996-02-29 Bayer Ag Verwendung von N-substituierten Phenothiazinen
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
US5697985A (en) * 1995-06-07 1997-12-16 Bayer Corporation Process for the preparation storage-stable dye dispersions
WO1999062548A1 (en) 1998-06-01 1999-12-09 Advanced Research And Technology Institute Methods and compositions for diagnosing tauopathies
JP2000344685A (ja) 1999-03-26 2000-12-12 Bf Kenkyusho:Kk アズールａ類似化合物によるアミロイドが蓄積する疾患の画像診断プローブおよびそれを含む画像診断用組成物
JP2000344684A (ja) 1999-03-26 2000-12-12 Bf Kenkyusho:Kk ピロニンｂ類似化合物によるアミロイドが蓄積する疾患の画像診断プローブおよびそれを含む画像診断用組成物
AU767726B2 (en) * 1999-04-30 2003-11-20 Pfizer Products Inc. Radiotracers for in vivo study of acetylcholinesterase and Alzheimer's disease
WO2001070699A1 (fr) 2000-03-22 2001-09-27 Bf Research Institute, Inc. Analogues d'azur a utilises comme sondes dans l'imagerie diagnostique des maladies dues a l'accumulation d'amyloide, et compositions renfermant ces analogues destinees a l'imagerie diagnostique
BRPI0113470B8 (pt) 2000-08-24 2021-05-25 Univ Pittsburgh composto de ligação amilóide, composição farmacêutica e métodos de síntese de composto, de detecção in vivo de depósitos amilóides num indivíduo e em tecido humano ou animal, de quantificação de depósito amilóide em tecido de biópsia ou postmortem e de distinção de um cérebro de doença de alzheimer de um cérebro normal
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) * 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
GB0117326D0 (en) 2001-07-16 2001-09-05 Univ Aberdeen Napthoquinone-type inhibitors of protein aggregation
US6953974B2 (en) * 2003-08-26 2005-10-11 Texas Instruments Incorporated EEPROM device and method for providing lower programming voltage
GB0322756D0 (en) 2003-09-29 2003-10-29 Univ Aberdeen Methods of chemical synthesis
ES2736160T3 (es) 2004-09-23 2019-12-26 Wista Lab Ltd Procedimientos de síntesis química y purificación de compuestos de diaminofenotiazinio que incluyen cloruro de metiltioninio (CMT)

Also Published As

Publication number Publication date
CN1578910A (zh) 2005-02-09
US20080219929A1 (en) 2008-09-11
US20100285605A1 (en) 2010-11-11
JP2004537034A (ja) 2004-12-09
PT1421389E (pt) 2012-07-10
CA2440794A1 (en) 2002-09-26
US7713962B2 (en) 2010-05-11
AU2002251172B2 (en) 2007-12-06
ATE556323T1 (de) 2012-05-15
US20040213736A1 (en) 2004-10-28
WO2002075318A2 (en) 2002-09-26
WO2002075318A3 (en) 2004-03-11
US8097615B2 (en) 2012-01-17
ES2386773T3 (es) 2012-08-30
DK1421389T3 (da) 2012-08-13
US7335652B2 (en) 2008-02-26
CN101696977A (zh) 2010-04-21
JP4288073B2 (ja) 2009-07-01
JP2009035566A (ja) 2009-02-19
EP1421389B1 (en) 2012-05-02
CA2440794C (en) 2012-05-01
EP1421389A2 (en) 2004-05-26
GB0106953D0 (en) 2001-05-09
CN101696977B (zh) 2014-02-19

Similar Documents

Publication Publication Date Title
HK1062044A1 (en) Neurofibrillary labels
GR3032843T3 (en) Methods and compositions for detecting binding of ligand pair using non-fluorescent label
DK0920631T3 (da) Fremgangsmåde til identifikation af forbindelser, som indvirker på interaktioner mellem RNA og RNA-bindende proteiner
WO2002018432A3 (de) Protein aus dem darm von wirbeltieren, welches cholesterin absorbiert, sowie verwendung dieses proteins zur identifizierung von inhibitoren des intestinalen cholesterintransports
WO2003062462A3 (en) Method for isolating nucleic acids and protein from a single sample
WO2007021825A3 (en) Treatment of proliferative disorders
WO2002016412A3 (en) Binding polypeptides for b lymphocyte stimulator protein (blys)
WO2002072778A3 (en) Method for identifying inhibitors of g protein coupled receptor signaling
WO2005114219A3 (en) Assays to identify irreversibly binding inhibitors of receptor tyrosine kinases
WO2008064304A3 (en) Compositions and methods for the identification of inhibitors of protein synthesis
WO2008060483A3 (en) Protein-protein interaction biosensors and methods of use thereof
WO2003076949A3 (en) Tagging and recovery of elements associated with target molecules
ATE426158T1 (de) Mikrofluidisches extraktionsverfahren
WO2006102547A3 (en) Method for purifying proteins
IL166492A (en) Method for isolating an intestinal cholesterol binding protein, intestinal cholesterol binding protein, its complexes and uses thereof
DE602004015953D1 (de) Festphase immunochromatographische testverfahren
WO2005036169A3 (en) Fluorescent probes for ribosomes and method of use
DK1246945T3 (da) Fremgangsmåde til identifikation af en mærkning anbragt på et fast legeme
ZA200807766B (en) Inhibition of GASC1
WO2002072606A3 (en) Epitope testing using hla
GB2427840A (en) Method and apparatus for the application of power material to substrates
WO2005019475A3 (en) Hypoxia-inducible protein 2 (hig2), a novel therapeutic potential target of renal cell carcinoma (rcc)
NO20025738D0 (no) Metode
WO2009137837A3 (en) Neuregulin/erbb signaling and integrin
WO2007095378A3 (en) Mass tagging for quantitative analysis of biomolecules using 13c labeled phenylisocyanate

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20220319